## Henry Kranzler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2882579/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics, 2019, 51, 63-75.	9.4	1,594
2	The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings Journal of Studies on Alcohol and Drugs, 1995, 56, 423-432.	2.4	1,068
3	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	13.5	935
4	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	9.4	629
5	A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients. Neuropsychopharmacology, 2003, 28, 1546-1552.	2.8	594
6	Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence. JAMA - Journal of the American Medical Association, 2005, 293, 1617.	3.8	545
7	Serotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. American Journal of Psychiatry, 1996, 153, 83-92.	4.0	509
8	Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug and Alcohol Dependence, 2004, 74, 265-272.	1.6	497
9	Topiramate for Treating Alcohol Dependence <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2007, 298, 1641.	3.8	490
10	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nature Neuroscience, 2018, 21, 1656-1669.	7.1	490
11	Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug and Alcohol Dependence, 2007, 86, 214-221.	1.6	410
12	Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects. Human Genetics, 1997, 101, 243-246.	1.8	393
13	Diagnosis and Pharmacotherapy of Alcohol Use Disorder. JAMA - Journal of the American Medical Association, 2018, 320, 815.	3.8	382
14	Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. Molecular Psychiatry, 2018, 23, 666-673.	4.1	374
15	Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis. Alcoholism: Clinical and Experimental Research, 2001, 25, 1335-1341.	1.4	365
16	International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nature Communications, 2019, 10, 4558.	5.8	363
17	Give them prizes and they will come: Contingency management for treatment of alcohol dependence Journal of Consulting and Clinical Psychology, 2000, 68, 250-257.	1.6	360
18	Genome-wide association study of alcohol dependence:significant findings in African- and European-Americans including novel risk loci. Molecular Psychiatry, 2014, 19, 41-49.	4.1	353

#	Article	IF	CITATIONS
19	Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nature Communications, 2019, 10, 1499.	5.8	346
20	Interaction of FKBP5 with Childhood Adversity on Risk for Post-Traumatic Stress Disorder. Neuropsychopharmacology, 2010, 35, 1684-1692.	2.8	299
21	Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry, 1995, 152, 391-397.	4.0	282
22	A Prospective Cohort Study Investigating Factors Associated With Depression During Medical Internship. Archives of General Psychiatry, 2010, 67, 557.	13.8	282
23	Give them prizes, and they will come: contingency management for treatment of alcohol dependence. Journal of Consulting and Clinical Psychology, 2000, 68, 250-7.	1.6	271
24	Genetics of two μ opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Molecular Psychiatry, 1999, 4, 476-483.	4.1	266
25	Allelic and haplotypic association ofGABRA2 with alcohol dependence. American Journal of Medical Genetics Part A, 2004, 129B, 104-109.	2.4	263
26	Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 79-84.	1.1	244
27	Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. Nature Neuroscience, 2020, 23, 809-818.	7.1	242
28	Buspirone Treatment of Anxious Alcoholics. Archives of General Psychiatry, 1994, 51, 720.	13.8	232
29	Interactive Effect of Stressful Life Events and the Serotonin Transporter 5-HTTLPR Genotype on Posttraumatic Stress Disorder Diagnosis in 2 Independent Populations. Archives of General Psychiatry, 2009, 66, 1201.	13.8	221
30	Acamprosate Efficacy in Alcoholâ€Dependent Patients: Summary of Results from Three Pivotal Trials. American Journal on Addictions, 2008, 17, 70-76.	1.3	209
31	Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug and Alcohol Dependence, 2009, 99, 345-349.	1.6	209
32	Early detection of harmful alcohol consumption: Comparison of clinical, laboratory, and self-report screening procedures. Addictive Behaviors, 1989, 14, 139-157.	1.7	206
33	Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: A meta-analysis. Drug and Alcohol Dependence, 2006, 83, 262-268.	1.6	203
34	Adverse childhood events as risk factors for substance dependence: Partial mediation by mood and anxiety disorders. Addictive Behaviors, 2010, 35, 7-13.	1.7	203
35	A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry,the, 2020, 7, 1032-1045.	3.7	200
36	Sertraline Treatment for Alcohol Dependence: Interactive Effects of Medication and Alcoholic Subtype. Alcoholism: Clinical and Experimental Research, 2000, 24, 1041-1049.	1.4	199

#	Article	IF	CITATIONS
37	Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia. Neuropsychopharmacology, 1994, 11, 195-200.	2.8	198
38	Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial. Neuropsychopharmacology, 2000, 22, 493-503.	2.8	198
39	Genome-Wide Association Study of Opioid Dependence: Multiple Associations Mapped to Calcium and Potassium Pathways. Biological Psychiatry, 2014, 76, 66-74.	0.7	192
40	CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case–control structured association study. Human Molecular Genetics, 2005, 14, 2421-2434.	1.4	191
41	Fluoxetine Treatment Seems to Reduce the Beneficial Effects of Cognitive-Behavioral Therapy in Type B Alcoholics. Alcoholism: Clinical and Experimental Research, 1996, 20, 1534-1541.	1.4	190
42	Association Between Alcoholism and ??-Amino Butyric Acid ??2 Receptor Subtype in a Russian Population. Alcoholism: Clinical and Experimental Research, 2005, 29, 493-498.	1.4	188
43	Correlates of co-occurring ADHD in drug-dependent subjects: Prevalence and features of substance dependence and psychiatric disorders. Addictive Behaviors, 2008, 33, 1199-1207.	1.7	187
44	Genome-wide association study of cocaine dependence and related traits: FAM53B identified as a risk gene. Molecular Psychiatry, 2014, 19, 717-723.	4.1	182
45	Diagnostic reliability of the Semi-structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug and Alcohol Dependence, 2005, 80, 303-312.	1.6	180
46	A haplotype at the DBH locus, associated with low plasma dopamine β-hydroxylase activity, also associates with cocaine-induced paranoia. Molecular Psychiatry, 2000, 5, 56-63.	4.1	179
47	Opioid Receptor Gene (OPRM1, OPRK1, and OPRD1) Variants and Response to Naltrexone Treatment for Alcohol Dependence: Results From the VA Cooperative Study. Alcoholism: Clinical and Experimental Research, 2007, 31, 070212174136005-???.	1.4	178
48	D4 Dopamine-Receptor (DRD4) Alleles and Novelty Seeking in Substance-Dependent, Personality-Disorder, and Control Subjects. American Journal of Human Genetics, 1997, 61, 1144-1152.	2.6	174
49	Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior. JAMA Psychiatry, 2017, 74, 1242.	6.0	174
50	Levels and patterns of alcohol consumption using timeline follow-back, daily diaries and real-time "electronic interviews" Journal of Studies on Alcohol and Drugs, 1998, 59, 447-454.	2.4	171
51	Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers Journal of Abnormal Psychology, 1997, 106, 545-553.	2.0	170
52	Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 387-393.	1.1	170
53	Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: a posttreatment natural history study Journal of Studies on Alcohol and Drugs, 1996, 57, 619-626.	2.4	167
54	A Functional Neuropeptide Y Leu7Pro Polymorphism Associated With Alcohol Dependence in a Large Population Sample From the United States. Archives of General Psychiatry, 2002, 59, 825.	13.8	165

#	Article	IF	CITATIONS
55	Topiramate Treatment for Heavy Drinkers: Moderation by a <i>GRIK1</i> Polymorphism. American Journal of Psychiatry, 2014, 171, 445-452.	4.0	164
56	Self-reports by alcohol and drug abuse inpatients: factors affecting reliability and validity. Addiction, 1992, 87, 1013-1024.	1.7	163
57	Serotonin Transporter Protein Gene Polymorphism and Personality Measures in African American and European American Subjects. American Journal of Psychiatry, 1998, 155, 1332-1338.	4.0	163
58	Interactive Effects of the Serotonin Transporter 5-HTTLPR Polymorphism and Stressful Life Events on College Student Drinking and Drug Use. Biological Psychiatry, 2007, 61, 609-616.	0.7	162
59	Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo-Controlled Clinical Trial. Alcoholism: Clinical and Experimental Research, 2004, 28, 1051-1059.	1.4	156
60	Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Human Molecular Genetics, 2006, 15, 3498-3507.	1.4	156
61	Association between two µ-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Human Molecular Genetics, 2006, 15, 807-819.	1.4	155
62	Genome-wide Association Study Identifies New Susceptibility Loci for Posttraumatic Stress Disorder. Biological Psychiatry, 2013, 74, 656-663.	0.7	150
63	GABRA2 Alleles Moderate the Subjective Effects of Alcohol, Which are Attenuated by Finasteride. Neuropsychopharmacology, 2005, 30, 1193-1203.	2.8	148
64	Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks. JAMA Psychiatry, 2016, 73, 472.	6.0	148
65	A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2018, 83, 1044-1053.	0.7	146
66	Effects of the 2011 Duty Hour Reforms on Interns and Their Patients. JAMA Internal Medicine, 2013, 173, 657.	2.6	144
67	The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Molecular Psychiatry, 2008, 13, 531-543.	4.1	143
68	A common polymorphism in serotonin receptor 1B mRNA moderates regulation by miR-96 and associates with aggressive human behaviors. Molecular Psychiatry, 2009, 14, 381-389.	4.1	143
69	Multivariate analysis of 1.5 million people identifies genetic associations with traits related to self-regulation and addiction. Nature Neuroscience, 2021, 24, 1367-1376.	7.1	137
70	Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium. Translational Psychiatry, 2016, 6, e769-e769.	2.4	136
71	Association of <i>OPRM1</i> Functional Coding Variant With Opioid Use Disorder. JAMA Psychiatry, 2020, 77, 1072.	6.0	135
72	Metaâ€Analysis of the Association of Alcoholâ€Related Social Media Use with Alcohol Consumption and Alcoholâ€Related Problems in Adolescents and Young Adults. Alcoholism: Clinical and Experimental Research, 2018, 42, 978-986.	1.4	134

#	Article	IF	CITATIONS
73	Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the ?-opioid receptor locus (OPRM1). American Journal of Medical Genetics Part A, 2003, 118B, 60-65.	2.4	132
74	Personality Disorders in Substance Abusers: Relation to Substance Use. Journal of Nervous and Mental Disease, 1998, 186, 87-95.	0.5	132
75	Validity of the SCID in substance abuse patients. Addiction, 1996, 91, 859-868.	1.7	131
76	Genomewide Linkage Scan for Opioid Dependence and Related Traits. American Journal of Human Genetics, 2006, 78, 759-769.	2.6	125
77	Reliability of DSM-IV diagnostic criteria using the semi-structured assessment for drug dependence and alcoholism (SSADDA). Drug and Alcohol Dependence, 2007, 91, 85-90.	1.6	124
78	Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism: Clinical and Experimental Research, 2001, 25, 1335-41.	1.4	124
79	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. Alcoholism: Clinical and Experimental Research, 2017, 41, 179-186.	1.4	123
80	Alcohol Dependence Genetics: Lessons Learned From Genome-Wide Association Studies (GWAS) and Post-GWAS Analyses. Alcoholism: Clinical and Experimental Research, 2015, 39, 1312-1327.	1.4	121
81	Genomewide linkage scan for cocaine dependence and related traits: Significant linkages for a cocaine-related trait and cocaine-induced paranoia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 136B, 45-52.	1.1	119
82	Serotonin Transporter Gene Polymorphism (5-HTTLPR) and Anxiety Reactivity in Daily Life: A Daily Process Approach to Gene-Environment Interaction. Psychosomatic Medicine, 2007, 69, 762-768.	1.3	119
83	Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case–control and family samples. Human Molecular Genetics, 2007, 16, 2844-2853.	1.4	118
84	Double-Blind Clinical Trial of Sertraline Treatment for Alcohol Dependence. Journal of Clinical Psychopharmacology, 2001, 21, 143-153.	0.7	117
85	Effects of Ondansetron in Early- Versus Late-Onset Alcoholics: A Prospective, Open-Label Study. Alcoholism: Clinical and Experimental Research, 2003, 27, 1150-1155.	1.4	114
86	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	0.7	114
87	Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence, 2003, 71, 219-228.	1.6	113
88	Utility of the AUDIT for identification of hazardous or harmful drinking in drug-dependent patients. Drug and Alcohol Dependence, 1997, 45, 157-163.	1.6	112
89	Diplotype Trend Regression Analysis of the ADH Gene Cluster and the ALDH2 Gene: Multiple Significant Associations with Alcohol Dependence. American Journal of Human Genetics, 2006, 78, 973-987.	2.6	110
90	Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals With Topiramate Treatment <subtitle>US Multisite Randomized Controlled Trial</subtitle> . Archives of Internal Medicine, 2008, 168, 1188.	4.3	109

#	Article	IF	CITATIONS
91	Genetics of alcohol dependence. Human Genetics, 2009, 126, 91-99.	1.8	109
92	Evidence of CNIH3 involvement in opioid dependence. Molecular Psychiatry, 2016, 21, 608-614.	4.1	109
93	Efficacy of Extended-Release Naltrexone in Alcohol-Dependent Patients Who Are Abstinent Before Treatment. Journal of Clinical Psychopharmacology, 2007, 27, 507-512.	0.7	108
94	Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry,the, 2017, 4, 469-476.	3.7	108
95	Practical population group assignment with selected informative markers: Characteristics and properties of Bayesian clustering via STRUCTURE. Genetic Epidemiology, 2005, 28, 302-312.	0.6	106
96	Nicotine Gum for Pregnant Smokers. Obstetrics and Gynecology, 2008, 112, 859-867.	1.2	106
97	PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH. Alcohol and Alcoholism, 2000, 35, 537-547.	0.9	105
98	A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology, 2004, 24, 421-428.	0.7	105
99	CNR1 Variation Modulates Risk for Drug and Alcohol Dependence. Biological Psychiatry, 2007, 62, 616-626.	0.7	105
100	Population genetics of a functional variant of the dopamine $\hat{l}^2$ -hydroxylase gene (DBH). , 1997, 74, 374-379.		104
101	Genome-Wide Association Study of Alcohol Dependence Implicates KIAA0040 on Chromosome 1q. Neuropsychopharmacology, 2012, 37, 557-566.	2.8	104
102	Physicians' opinions about medications to treat alcoholism. Addiction, 2003, 98, 617-626.	1.7	103
103	Variation in Nicotinic Acetylcholine Receptor Genes is Associated with Multiple Substance Dependence Phenotypes. Neuropsychopharmacology, 2010, 35, 1921-1931.	2.8	103
104	ADH4 Gene Variation is Associated with Alcohol Dependence and Drug Dependence in European Americans: Results from HWD Tests and Case–Control Association Studies. Neuropsychopharmacology, 2006, 31, 1085-1095.	2.8	102
105	Assessment of Medication Compliance in Alcoholics through UV Light Detection of a Riboflavin Tracer. Alcoholism: Clinical and Experimental Research, 1996, 20, 1412-1417.	1.4	101
106	<i>ALDH2</i> is associated to alcohol dependence and is the major genetic determinant of "daily maximum drinks―in a GWAS study of an isolated rural chinese sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 103-110.	1.1	101
107	Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behavior Genetics, 2016, 46, 151-169.	1.4	98
108	Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. American Journal of Medical Genetics Part A, 2003, 120B, 97-108.	2.4	97

#	Article	IF	CITATIONS
109	Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. Archives of General Psychiatry, 1994, 51, 898.	13.8	96
110	Ethical Considerations for Administering Alcohol or Alcohol Cues to Treatment‣eeking Alcoholics in a Research Setting: Can the Benefits to Society Outweigh the Risks to the Individual?. Alcoholism: Clinical and Experimental Research, 2009, 33, 1508-1512.	1.4	94
111	Haplotypic Variants in <i>DRD2</i> , <i>ANKK1</i> , <i>TTC12</i> , and <i>NCAM1</i> are Associated With Comorbid Alcohol and Drug Dependence. Alcoholism: Clinical and Experimental Research, 2008, 32, 2117-2127.	1.4	93
112	A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology, 2008, 28, 5-12.	0.7	93
113	Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug and Alcohol Dependence, 2013, 127, 215-219.	1.6	93
114	Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder. Neuropsychopharmacology, 2014, 39, 907-918.	2.8	93
115	Sustained-Release Naltrexone for Alcoholism Treatment: A Preliminary Study. Alcoholism: Clinical and Experimental Research, 1998, 22, 1074-1079.	1.4	91
116	Psychometric Properties of the Short Index of Problems as a Measure of Recent Alcohol-Related Problems. Alcoholism: Clinical and Experimental Research, 2003, 27, 1436-1441.	1.4	90
117	Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10. Addiction, 1993, 88, 337-348.	1.7	89
118	Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology, 1998, 139, 44-52.	1.5	89
119	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. World Journal of Biological Psychiatry, 2011, 12, 160-187.	1.3	88
120	ADH4 gene variation is associated with alcohol and drug dependence: results from family controlled and population-structured association studies. Pharmacogenetics and Genomics, 2005, 15, 755-768.	0.7	87
121	Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. Translational Psychiatry, 2015, 5, e651-e651.	2.4	86
122	Axis I and Axis II disorders in alcoholics and drug addicts: fact or artifact?. Journal of Studies on Alcohol and Drugs, 2000, 61, 101-110.	2.4	85
123	Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Molecular Psychiatry, 2017, 22, 346-352.	4.1	85
124	Does affect mediate the association between daily events and alcohol use?. Journal of Studies on Alcohol and Drugs, 2000, 61, 862-871.	2.4	84
125	Sertraline Treatment of Co-occurring Alcohol Dependence and Major Depression. Journal of Clinical Psychopharmacology, 2006, 26, 13-20.	0.7	84
126	Markers in the 5′-Region of GABRG1 Associate to Alcohol Dependence and are in Linkage Disequilibrium with Markers in the Adjacent GABRA2 Gene. Neuropsychopharmacology, 2008, 33, 837-848.	2.8	84

#	Article	IF	CITATIONS
127	Genetic associations with suicide attempt severity and genetic overlap with major depression. Translational Psychiatry, 2019, 9, 22.	2.4	84
128	Ritanserin in the treatment of alcohol dependence - a multi-center clinical trial. Psychopharmacology, 1996, 128, 206-215.	1.5	83
129	A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence. Journal of Clinical Psychopharmacology, 2011, 31, 22-30.	0.7	83
130	Arrayâ€Based Profiling of <scp>DNA</scp> Methylation Changes Associated with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2013, 37, E108-15.	1.4	83
131	Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2018, 42, 2453-2465.	1.4	82
132	Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry,the, 2019, 6, 1054-1067.	3.7	82
133	Genome-wide Association Study of Maximum Habitual Alcohol Intake in >140,000 U.S. European and African American Veterans Yields Novel Risk Loci. Biological Psychiatry, 2019, 86, 365-376.	0.7	82
134	Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. Molecular Psychiatry, 2020, 25, 1673-1687.	4.1	82
135	A randomized clinical trial of brief interventions in primary health care: summary of a WHO project. Addiction, 1994, 89, 657-660.	1.7	81
136	Validity of psychiatric diagnoses in patients with substance use disorders: Is the interview more important than the interviewer?. Comprehensive Psychiatry, 1995, 36, 278-288.	1.5	81
137	Factor replicability and validity of the Temperament and Character Inventory in substance-dependent patients Psychological Assessment, 1999, 11, 514-524.	1.2	81
138	Variation in <i>GABRA2</i> Predicts Drinking Behavior in Project MATCH Subjects. Alcoholism: Clinical and Experimental Research, 2007, 31, 1780-1787.	1.4	81
139	Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress. Journal of Studies on Alcohol and Drugs Supplement, 2014, , 79-88.	3.7	81
140	Genome-wide association study across European and African American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. Molecular Psychiatry, 2018, 23, 1911-1919.	4.1	80
141	Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits. Nature Communications, 2020, 11, 5562.	5.8	80
142	D2 Dopamine Receptor Gene (DRD2) Allele and Haplotype Frequencies in Alcohol Dependent and Control Subjects No Association with Phenotype or Severity of Phenotype. Neuropsychopharmacology, 1999, 20, 640-649.	2.8	79
143	Genome-Wide Association Study of Nicotine Dependence in American Populations: Identification of Novel Risk Loci in Both African-Americans and European-Americans. Biological Psychiatry, 2015, 77, 493-503.	0.7	78
144	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. JAMA Psychiatry, 2019, 76, 374.	6.0	77

#	Article	IF	CITATIONS
145	Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism Journal of Consulting and Clinical Psychology, 1994, 62, 1116-1126.	1.6	76
146	Correlates of Electronic Cigarettes Use Before and During Pregnancy. Nicotine and Tobacco Research, 2017, 19, 585-590.	1.4	76
147	Reliability of personality disorder symptoms and personality traits in substance-dependent inpatients Journal of Abnormal Psychology, 2001, 110, 341-352.	2.0	75
148	Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology, 2001, 154, 397-402.	1.5	74
149	Mecamylamine Modifies the Pharmacokinetics and Reinforcing Effects of Alcohol. Alcoholism: Clinical and Experimental Research, 2002, 26, 326-331.	1.4	74
150	Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression. JAMA Psychiatry, 2017, 74, 1234.	6.0	74
151	A metaâ€∎nalysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction, 2019, 114, 1547-1555.	1.7	74
152	Targeted Versus Daily Naltrexone: Secondary Analysis of Effects on Average Daily Drinking. Alcoholism: Clinical and Experimental Research, 2006, 30, 860-865.	1.4	73
153	Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence. JAMA Psychiatry, 2017, 74, 1153.	6.0	73
154	Population Studies of Polymorphisms at Loci of Neuropsychiatric Interest (Tryptophan Hydroxylase) Tj ETQq0 0 (	0 rgBT /0\ 1.3	verlock 10 Tf 5 72
155	Genomewide Linkage Scan for Nicotine Dependence: Identification of a Chromosome 5 Risk Locus. Biological Psychiatry, 2007, 61, 119-126.	0.7	72
156	Integrating GWASs and Human Protein Interaction Networks Identifies a Gene Subnetwork Underlying Alcohol Dependence. American Journal of Human Genetics, 2013, 93, 1027-1034.	2.6	72
157	Association study of theCNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 499-503.	1.1	71
158	The Pharmacogenetics of Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2015, 39, 391-402.	1.4	71
159	The validity of self-reported cocaine use in two groups of cocaine abusers Journal of Consulting and Clinical Psychology, 1999, 67, 37-42.	1.6	69
160	Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism: Clinical and Experimental Research, 2000, 24, 1041-9.	1.4	69
161	Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug and Alcohol Dependence, 1995, 38, 203-211.	1.6	68
162	Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers. Alcoholism: Clinical and Experimental Research, 2008, 32, 1159-1166.	1.4	68

#	Article	IF	CITATIONS
163	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	9.4	68
164	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World Journal of Biological Psychiatry, 2008, 9, 6-23.	1.3	67
165	Reduction of Alcohol Drinking in Young Adults by Naltrexone. Journal of Clinical Psychiatry, 2015, 76, e207-e213.	1.1	67
166	Genetic Relationship between Schizophrenia and Nicotine Dependence. Scientific Reports, 2016, 6, 25671.	1.6	67
167	Validity of the SCID in substance abuse patients. Addiction, 1996, 91, 859-68.	1.7	67
168	Association of psychiatric and substance use disorder comorbidity with cocaine dependence severity and treatment utilization in cocaine-dependent individuals. Drug and Alcohol Dependence, 2009, 99, 193-203.	1.6	66
169	Targeted Naltrexone for Problem Drinkers. Journal of Clinical Psychopharmacology, 2009, 29, 350-357.	0.7	66
170	Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. Journal of Chromatography A, 1990, 499, 601-608.	1.8	65
171	Social Drinking as a Health and Psychosocial Risk Factor. Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism, 1987, 5, 373-402.	0.4	65
172	Targeted naltrexone treatment of early problem drinkers. Addictive Behaviors, 1997, 22, 431-436.	1.7	64
173	Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans. Biological Psychiatry, 2018, 84, 762-770.	0.7	64
174	Association Study of Alcoholism Subtypes with a Functional Promoter Polymorphism in the Serotonin Transporter Protein Gene. Alcoholism: Clinical and Experimental Research, 2002, 26, 1330-1335.	1.4	63
175	Targeted Naltrexone for Early Problem Drinkers. Journal of Clinical Psychopharmacology, 2003, 23, 294-304.	0.7	63
176	Childhood Adversity Increases Risk for Nicotine Dependence and Interacts with α5 Nicotinic Acetylcholine Receptor Genotype Specifically in Males. Neuropsychopharmacology, 2012, 37, 669-676.	2.8	63
177	Risks of Alcohol Use Disorders Related to Drinking Patterns in the U.S. General Population. Journal of Studies on Alcohol and Drugs, 2014, 75, 319-327.	0.6	63
178	Sweet Taste Preference as a Risk Factor for Alcohol Dependence. American Journal of Psychiatry, 2001, 158, 813-815.	4.0	62
179	Barriers to the Use of Medications to Treat Alcoholism. American Journal on Addictions, 2003, 12, 281-294.	1.3	62
180	Association of Markers in the 3′ Region of the GluR5 Kainate Receptor Subunit Gene to Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2009, 33, 925-930.	1.4	62

#	Article	IF	CITATIONS
181	Rare Nonsynonymous Variants in Alpha-4 Nicotinic Acetylcholine Receptor Gene Protect Against Nicotine Dependence. Biological Psychiatry, 2011, 70, 528-536.	0.7	62
182	Serotonin transporter <i>5â€HTTLPR</i> genotype moderates the effects of childhood adversity on posttraumatic stress disorder risk: A replication study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 644-652.	1,1	62
183	Bromocriptine and cocaine cue reactivity in cocaine-dependent patients. Addiction, 1992, 87, 1537-1548.	1.7	61
184	Pharmacogenetics of Alcohol and Alcohol Dependence Treatment. Current Pharmaceutical Design, 2010, 16, 2141-2148.	0.9	61
185	Effects of Naltrexone on Smoking Cessation Outcomes and Weight Gain in Nicotine-Dependent Men and Women. Journal of Clinical Psychopharmacology, 2012, 32, 630-636.	0.7	61
186	Personalized Treatment of Alcohol Dependence. Current Psychiatry Reports, 2012, 14, 486-493.	2.1	61
187	Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2015, 39, 1557-1570.	1.4	61
188	Anxiety and Depression in Substance Abuse: Clinical Implications. Medical Clinics of North America, 1988, 72, 867-885.	1.1	60
189	Dual Diagnosis: Alcoholism and Coâ€Morbid Psychiatric Disorders. American Journal on Addictions, 2003, 12, s26-s40.	1.3	59
190	Genome-wide association study of smoking trajectory and meta-analysis of smoking status in 842,000 individuals. Nature Communications, 2020, 11, 5302.	5.8	59
191	Validity of the longitudinal, expert, all data procedure for psychiatric diagnosis in patients with psychoactive substance use disorders. Drug and Alcohol Dependence, 1997, 45, 93-104.	1.6	58
192	Using Daily Interactive Voice Response Technology to Measure Drinking and Related Behaviors in a Pharmacotherapy Study. Alcoholism: Clinical and Experimental Research, 2004, 28, 1060-1064.	1.4	58
193	Genetic risk prediction and neurobiological understanding of alcoholism. Translational Psychiatry, 2014, 4, e391-e391.	2.4	58
194	Genomewide Association Study for Maximum Number of Alcoholic Drinks in European Americans and African Americans. Alcoholism: Clinical and Experimental Research, 2015, 39, 1137-1147.	1.4	58
195	No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. Biological Psychiatry, 1999, 45, 340-345.	0.7	57
196	Measurement of admixture proportions and description of admixture structure in different U.S. populations. Human Mutation, 2009, 30, 1299-1309.	1.1	57
197	Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. Journal of Human Genetics, 2012, 57, 670-675.	1.1	57
198	Typologies of drug dependence: comparative validity of a multivariate and four univariate models. Drug and Alcohol Dependence, 2004, 73, 289-300.	1.6	56

#	Article	IF	CITATIONS
199	Population-specific effects of the Asn40Asp polymorphism at the μ-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenetics and Genomics, 2007, 17, 1031-1038.	0.7	56
200	Interaction between Two Independent CNR1 Variants Increases Risk for Cocaine Dependence in European Americans: A Replication Study in Family-Based Sample and Population-Based Sample. Neuropsychopharmacology, 2009, 34, 1504-1513.	2.8	56
201	Associations between alcohol consumption and gray and white matter volumes in the UK Biobank. Nature Communications, 2022, 13, 1175.	5.8	56
202	Validity of the Obsessive Compulsive Drinking Scale (OCDS): Does Craving Predict Drinking Behavior?. Alcoholism: Clinical and Experimental Research, 1999, 23, 108-114.	1.4	55
203	Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). Drug and Alcohol Dependence, 2005, 80, 23-33.	1.6	55
204	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. World Journal of Biological Psychiatry, 2017, 18, 86-119.	1.3	55
205	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2022, 328, 151.	3.8	55
206	Problems Associated with Average Alcohol Consumption and Frequency of Intoxication in a Medical Population. Alcoholism: Clinical and Experimental Research, 1990, 14, 119-126.	1.4	54
207	A <i>CRHR1</i> haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in Africanâ€American women. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 960-968.	1.1	54
208	No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. Molecular Psychiatry, 2012, 17, 239-241.	4.1	54
209	Rate of progression from first use to dependence on cocaine or opioids: A cross-substance examination of associated demographic, psychiatric, and childhood risk factors. Addictive Behaviors, 2014, 39, 473-479.	1.7	54
210	DRD2 Allele Frequencies and Linkage Disequilibria, Including the -141CIns/DelPromoter Polymorphism, in European-American, African-American, and Japanese Subjects. Genomics, 1998, 51, 21-26.	1.3	53
211	Topiramate for Smoking Cessation: A Randomized, Placebo-Controlled Pilot Study. Nicotine and Tobacco Research, 2014, 16, 288-296.	1.4	53
212	Personality Disorder and Dimension Differences Between Type A and Type B Substance Abusers. Journal of Personality Disorders, 1998, 12, 1-12.	0.8	52
213	<i>GABRA2</i> markers moderate the subjective effects of alcohol. Addiction Biology, 2013, 18, 357-369.	1.4	52
214	Effects of nicotine deprivation on urges to drink and smoke in alcoholic smokers. Addiction, 2003, 98, 913-921.	1.7	51
215	The Type A/Type B Distinction Annals of the New York Academy of Sciences, 1994, 708, 23-33.	1.8	50
216	Neuropsychologic findings in cocaine-dependent outpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 1061-1076.	2.5	50

#	Article	IF	CITATIONS
217	Drinking to cope: a comparison of questionnaire and electronic diary reports Journal of Studies on Alcohol and Drugs, 2005, 66, 121-129.	2.4	50
218	5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. Psychiatric Genetics, 2011, 21, 240-248.	0.6	50
219	Barriers to the Use of Medications to Treat Alcoholism. American Journal on Addictions, 2003, 12, 281-294.	1.3	49
220	Subjective effects and changes in steroid hormone concentrations in humans following acute consumption of alcohol. Psychopharmacology, 2006, 186, 451-461.	1.5	49
221	Association of Alcohol or Other Drug Dependence with Alleles of the mu Opioid Receptor Gene (OPRM1). Alcoholism: Clinical and Experimental Research, 1998, 22, 1359-1362.	1.4	48
222	Co-occurrence of Axis I and Axis II disorders in substance abusers. Acta Psychiatrica Scandinavica, 2000, 101, 110-118.	2.2	48
223	Intronic variants in the dopa decarboxylase ( DDC ) gene are associated with smoking behavior in European-Americans and African-Americans. Human Molecular Genetics, 2006, 15, 2192-2199.	1.4	48
224	Persistence with oral naltrexone for alcohol treatment: implications for health are utilization. Addiction, 2008, 103, 1801-1808.	1.7	48
225	Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials. Alcoholism: Clinical and Experimental Research, 2014, 38, 2826-2834.	1.4	48
226	Personality disorders and associated features in cocaine-dependent inpatients. Comprehensive Psychiatry, 1994, 35, 335-340.	1.5	47
227	A genome-wide gene-by-trauma interaction study of alcohol misuse in two independent cohorts identifies PRKG1 as a risk locus. Molecular Psychiatry, 2018, 23, 154-160.	4.1	47
228	Genomic influences on self-reported childhood maltreatment. Translational Psychiatry, 2020, 10, 38.	2.4	47
229	Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Molecular Psychiatry, 2001, 6, 501-502.	4.1	46
230	Comorbid Psychiatric Diagnoses and Their Association with Cocaine-Induced Psychosis in Cocaine-Dependent Subjects. American Journal on Addictions, 2007, 16, 343-351.	1.3	46
231	Effect of Extendedâ€Release Naltrexone (XRâ€NTX) on Quality of Life in Alcoholâ€Dependent Patients. Alcoholism: Clinical and Experimental Research, 2009, 33, 350-356.	1.4	46
232	Linkage Analysis Followed by Association Show NRG1 Associated with Cannabis Dependence in African Americans. Biological Psychiatry, 2012, 72, 637-644.	0.7	46
233	Variation in <i><scp>OPRM1</scp></i> moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addiction Biology, 2013, 18, 193-201.	1.4	46
234	Oxytocin receptor gene polymorphisms, attachment, and PTSD: Results from the National Health and Resilience in Veterans Study. Journal of Psychiatric Research, 2017, 94, 139-147.	1.5	46

#	Article	IF	CITATIONS
235	Pharmacotherapy of alcohol use disorders: seventy-five years of progress. Journal of Studies on Alcohol and Drugs Supplement, 2014, 75 Suppl 17, 79-88.	3.7	46
236	Use of Buspirone in an Adolescent with Overanxious Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1988, 27, 789-790.	0.3	45
237	Electroencephalographic activity and mood in cocaine-dependent outpatients: Effects of cocaine cue exposure. Biological Psychiatry, 1994, 36, 189-197.	0.7	45
238	Polymorphism of the 5-HT1B Receptor Gene (HTR1B) Strong Within-Locus Linkage Disequilibrium without Association to Antisocial Substance Dependence. Neuropsychopharmacology, 2002, 26, 115-122.	2.8	45
239	Variation at APOE and STH loci and Alzheimer's disease. Behavioral and Brain Functions, 2006, 2, 13.	1.4	45
240	Functional polymorphisms in the serotonin 1B receptor gene ( <i>HTR1B</i> ) predict selfâ€reported anger and hostility among young men. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 67-78.	1.1	45
241	A GABRA2 Variant Is Associated with Increased Stimulation and â€~High' Following Alcohol Administration. Alcohol and Alcoholism, 2014, 49, 1-9.	0.9	45
242	Effects of naltrexone on cue-elicited craving for alcohol and cocaine. Drug and Alcohol Dependence, 1997, 49, 9-16.	1.6	44
243	Pharmacotherapies to enhance smoking cessation during pregnancy. Drug and Alcohol Review, 2003, 22, 191-202.	1.1	44
244	<i><scp>GABRA</scp>2</i> Alcohol Dependence Risk Allele is Associated with Reduced Expression of Chromosome 4p12 GABA <sub>A</sub> Subunit Genes in Human Neural Cultures. Alcoholism: Clinical and Experimental Research, 2015, 39, 1654-1664.	1.4	44
245	Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response. Alcoholism: Clinical and Experimental Research, 2019, 43, 2395-2405.	1.4	44
246	Cognitive Behavioral Therapy for Insomnia in Alcoholâ€Đependent Veterans: A Randomized, Controlled Pilot Study. Alcoholism: Clinical and Experimental Research, 2019, 43, 1244-1253.	1.4	44
247	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction, 2020, 115, 1668-1680.	1.7	44
248	Genomewide Association Study of Alcohol Dependence Identifies Risk Loci Altering Ethanolâ€Response Behaviors in Model Organisms. Alcoholism: Clinical and Experimental Research, 2017, 41, 911-928.	1.4	43
249	Reduction in Nonabstinent <scp>WHO</scp> Drinking Risk Levels and Change in Risk for Liver Disease and Positive <scp>AUDIT</scp> Scores: Prospective 3â€Year Followâ€Up Results in the <scp>U.S.</scp> General Population. Alcoholism: Clinical and Experimental Research, 2018, 42, 2256-2265.	1.4	43
250	Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress. Journal of Studies on Alcohol and Drugs Supplement, 2014, 75, 79-88.	3.7	43
251	Placebo-Controlled Trial of Zonisamide for the Treatment of Alcohol Dependence. Journal of Clinical Psychopharmacology, 2010, 30, 318-322.	0.7	42
252	Pilot Study of i <scp>PS</scp> â€Derived Neural Cells to Examine Biologic Effects of Alcohol on Human Neurons In Vitro. Alcoholism: Clinical and Experimental Research, 2012, 36, 1678-1687.	1.4	42

#	Article	IF	CITATIONS
253	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. Drug and Alcohol Dependence, 2019, 197, 228-235.	1.6	42
254	Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug and Alcohol Dependence, 2006, 84, 77-84.	1.6	41
255	A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men Journal of Consulting and Clinical Psychology, 2012, 80, 863-875.	1.6	41
256	Profiling of Childhood Adversity-Associated DNA Methylation Changes in Alcoholic Patients and Healthy Controls. PLoS ONE, 2013, 8, e65648.	1.1	41
257	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. Alcoholism: Clinical and Experimental Research, 2019, 43, 979-987.	1.4	41
258	Generalizability of the Type A/Type B Distinction Across Different Psychoactive Substances. American Journal of Drug and Alcohol Abuse, 1996, 22, 449-462.	1.1	40
259	Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. American Journal of Medical Genetics Part A, 2004, 127B, 42-47.	2.4	40
260	Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans. Human Molecular Genetics, 2007, 16, 380-390.	1.4	40
261	Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity. Addictive Behaviors, 2015, 50, 165-172.	1.7	40
262	The Interplay Between Risky Sexual Behaviors and Alcohol Dependence: Genome-Wide Association and Neuroimaging Support for LHPP as a Risk Gene. Neuropsychopharmacology, 2017, 42, 598-605.	2.8	40
263	Evaluation of a point-of-care testing product for drugs of abuse; testing site is a key variable. Drug and Alcohol Dependence, 1995, 40, 55-62.	1.6	39
264	Personality and substance use disorders as predictors of criminality. Comprehensive Psychiatry, 2000, 41, 276-283.	1.5	39
265	Targeted Naltrexone Treatment Moderates the Relations Between Mood and Drinking Behavior Among Problem Drinkers Journal of Consulting and Clinical Psychology, 2004, 72, 317-327.	1.6	39
266	<i>GABRG1</i> and <i>GABRA2</i> Variation Associated with Alcohol Dependence in African Americans. Alcoholism: Clinical and Experimental Research, 2012, 36, 588-593.	1.4	39
267	Identification of methylation quantitative trait loci (mQTLs) influencing promoter DNA methylation of alcohol dependence risk genes. Human Genetics, 2014, 133, 1093-1104.	1.8	39
268	Genome-Wide Association Study of Copy Number Variations (CNVs) with Opioid Dependence. Neuropsychopharmacology, 2015, 40, 1016-1026.	2.8	39
269	Genome-wide association study identifies a novel locus for cannabis dependence. Molecular Psychiatry, 2018, 23, 1293-1302.	4.1	39
270	Family-Based study of DRD2 alleles in alcohol and drug dependence. American Journal of Medical Genetics Part A, 2000, 96, 659-664.	2.4	38

#	Article	IF	CITATIONS
271	Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism. Biological Psychiatry, 2002, 51, 652-658.	0.7	38
272	The contribution of genetics to addiction therapy approaches. , 2005, 108, 86-93.		38
273	Longitudinal, Expert, All Data Procedure for Psychiatric Diagnosis in Patients with Psychoactive Substance Use Disorders. Journal of Nervous and Mental Disease, 1994, 182, 277-283.	0.5	37
274	Elevated Rates of Early Discontinuation from Pharmacotherapy Trials in Alcoholics and Drug Abusers. Alcoholism: Clinical and Experimental Research, 1996, 20, 16-20.	1.4	37
275	Alleles of a Functional Serotonin Transporter Promoter Polymorphism Are Associated With Major Depression in Alcoholics. Alcoholism: Clinical and Experimental Research, 2003, 27, 1402-1408.	1.4	37
276	What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?. Nicotine and Tobacco Research, 2009, 11, 1265-1273.	1.4	37
277	Improved methods to identify stable, highly heritable subtypes of opioid use and related behaviors. Addictive Behaviors, 2012, 37, 1138-1144.	1.7	37
278	Naltrexone and Brief Counseling to Reduce Heavy Drinking. American Journal on Addictions, 1994, 3, 91-99.	1.3	36
279	Nefazodone Treatment of Comorbid Alcohol Dependence and Major Depression. Alcoholism: Clinical and Experimental Research, 2004, 28, 433-440.	1.4	36
280	Association study of personality factors and the Asn40Asp polymorphism at the μ-opioid receptor gene (OPRM1). Psychiatric Genetics, 2004, 14, 89-92.	0.6	36
281	DSM-5 gambling disorder: Prevalence and characteristics in a substance use disorder sample Experimental and Clinical Psychopharmacology, 2014, 22, 50-56.	1.3	36
282	Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?. Addiction, 2017, 112, 2086-2094.	1.7	36
283	Serum Prolactin Level, Craving, and Early Discharge from Treatment in Cocaine-Dependent Patients. American Journal of Drug and Alcohol Abuse, 1992, 18, 187-195.	1.1	35
284	The effect of cigarette smoking on fetal heart rate characteristics*1. Obstetrics and Gynecology, 2002, 99, 751-755.	1.2	35
285	Dense Genomewide Linkage Scan for Alcohol Dependence in African Americans: Significant Linkage on Chromosome 10. Biological Psychiatry, 2009, 65, 111-115.	0.7	35
286	Treatment of Inhalant-Induced Psychotic Disorder With Carbamazepine Versus Haloperidol. Psychiatric Services, 1998, 49, 812-815.	1.1	34
287	GRIK1 Genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink. International Journal of Neuropsychopharmacology, 2014, 17, 1549-1556.	1.0	34
288	Genetic Vulnerability to Menthol Cigarette Preference in Women. Nicotine and Tobacco Research, 2015, 17, 1416-1420.	1.4	34

#	Article	IF	CITATIONS
289	Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcoholism: Clinical and Experimental Research, 2002, 26, 326-31.	1.4	34
290	The validity of cocaine dependence subtypes. Addictive Behaviors, 2008, 33, 41-53.	1.7	33
291	Variation in Genes Encoding the Neuroactive Steroid Synthetic Enzymes 5α-Reductase Type 1 and 3α-Reductase Type 2 Is Associated With Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2011, 35, 946-952.	1.4	33
292	Phenome-Wide Association Study for Alcohol and Nicotine Risk Alleles in 26394 Women. Neuropsychopharmacology, 2016, 41, 2688-2696.	2.8	33
293	Dental pathology and alcohol-related indicators in an outpatient clinic sample. Community Dentistry and Oral Epidemiology, 1990, 18, 204-207.	0.9	32
294	Variant detection at the δ opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Human Genetics, 2000, 107, 86-88.	1.8	32
295	Transdermal nicotine for smoking cessation in postmenopausal women. Addictive Behaviors, 2007, 32, 296-309.	1.7	32
296	Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol. Alcoholism: Clinical and Experimental Research, 2008, 32, 573-579.	1.4	32
297	Molecular genetic overlap between posttraumatic stress disorder and sleep phenotypes. Sleep, 2020, 43, .	0.6	32
298	Sex-stratified gene-by-environment genome-wide interaction study of trauma, posttraumatic-stress, and suicidality. Neurobiology of Stress, 2021, 14, 100309.	1.9	32
299	Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcoholism: Clinical and Experimental Research, 1998, 22, 1074-9.	1.4	32
300	PHARMACOLOGIC TREATMENTS FOR DRUG AND ALCOHOL DEPENDENCE. Psychiatric Clinics of North America, 1999, 22, 401-423.	0.7	31
301	Title is missing!. Journal of Clinical Psychopharmacology, 2003, 23, 294-304.	0.7	31
302	Pro-Opiomelanocortin Gene Variation Related to Alcohol or Drug Dependence: Evidence and Replications Across Family- and Population-based Studies. Biological Psychiatry, 2009, 66, 128-136.	0.7	31
303	Methamphetamine and Paranoia: The Methamphetamine Experience Questionnaire. American Journal on Addictions, 2010, 19, 155-168.	1.3	31
304	Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environment. Psychopharmacology, 2014, 231, 3609-3618.	1.5	31
305	Connecting the dots, genome-wide association studies in substance use. Molecular Psychiatry, 2016, 21, 733-735.	4.1	31
306	A putative causal relationship between genetically determined female body shape and posttraumatic stress disorder. Genome Medicine, 2017, 9, 99.	3.6	31

#	Article	IF	CITATIONS
307	Carbamazepine and cocaine-cue reactivity. Drug and Alcohol Dependence, 1995, 39, 213-221.	1.6	30
308	Association between polymorphisms in catecholâ€ <i>O</i> â€methyltransferase ( <i>COMT</i> ) and cocaineâ€induced paranoia in Europeanâ€American and Africanâ€American populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 651-660.	1.1	30
309	The 5â€HTTLPR polymorphism moderates the effect of stressful life events on drinking behavior in college students of African descent. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 484-490.	1.1	30
310	Varenicline and neuronal nicotinic acetylcholine receptors: A new approach to the treatment of coâ€occurring alcohol and nicotine addiction?. American Journal on Addictions, 2013, 22, 453-459.	1.3	30
311	Genomewide Study of Epigenetic Biomarkers of Opioid Dependence in European- American Women. Scientific Reports, 2019, 9, 4660.	1.6	30
312	A Functional Serotonin Transporter Gene Polymorphism and Depressive Effects Associated With Interferon-Â Treatment. Psychosomatics, 2010, 51, 137-148.	2.5	30
313	An Interpersonal Model of Addiction Relapse. Addictive Disorders and Their Treatment, 2013, 12, 183-192.	0.5	29
314	Validity of the Distinction Between "Substanceâ€Induced―and "Independent―Depression and Anxiety Disorders. American Journal on Addictions, 1995, 4, 107-117.	1.3	28
315	No association between D3 dopamine receptor (DRD3) alleles and cocaine dependence. Addiction Biology, 1996, 1, 281-287.	1.4	28
316	Does Effect Size in Naltrexone Trials for Alcohol Dependence Differ for Single-Site vs. Multi-Center Studies?. Alcoholism: Clinical and Experimental Research, 2005, 29, 983-988.	1.4	28
317	Cognitive Flexibility is Associated with KIBRA Variant and Modulated by Recent Tobacco Use. Neuropsychopharmacology, 2009, 34, 2508-2516.	2.8	28
318	A Genomewide Linkage Scan of Cocaine Dependence and Major Depressive Episode in Two Populations. Neuropsychopharmacology, 2011, 36, 2422-2430.	2.8	28
319	M3: an improved SNP calling algorithm for Illumina BeadArray data. Bioinformatics, 2012, 28, 358-365.	1.8	28
320	The Joint Effects of <i><scp>ADH</scp>1B</i> Variants and Childhood Adversity on Alcohol Related Phenotypes in Africanâ€American and Europeanâ€American Women and Men. Alcoholism: Clinical and Experimental Research, 2014, 38, 2907-2914.	1.4	28
321	Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2015, 39, 1571-1581.	1.4	28
322	Shared genetic risk between eating disorder†and substanceâ€useâ€related phenotypes: Evidence from genomeâ€wide association studies. Addiction Biology, 2021, 26, e12880.	1.4	28
323	Validity of the Obsessive Compulsive Drinking Scale (OCDS): does craving predict drinking behavior?. Alcoholism: Clinical and Experimental Research, 1999, 23, 108-14.	1.4	28
324	NOTCH4 gene haplotype is associated with schizophrenia in African Americans. Biological Psychiatry, 2004, 55, 112-117.	0.7	27

#	Article	IF	CITATIONS
325	Human clock, PER1 and PER2 polymorphisms: lack of association with cocaine dependence susceptibility and cocaine-induced paranoia. Psychiatric Genetics, 2006, 16, 245-249.	0.6	27
326	Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. Journal of Human Genetics, 2010, 55, 278-284.	1.1	27
327	Association of <i>CHRNA4</i> polymorphisms with smoking behavior in two populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 421-429.	1.1	27
328	Comparing the utility of homogeneous subtypes of cocaine use and related behaviors with DSMâ€ŀV cocaine dependence as traits for genetic association analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 148-156.	1.1	27
329	Polygenic risk for alcohol dependence associates with alcohol consumption, cognitive function and social deprivation in a populationâ€based cohort. Addiction Biology, 2016, 21, 469-480.	1.4	27
330	Systematic review and metaâ€analysis of the moderating effect of rs1799971 in <i>OPRM1</i> , the muâ€opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction, 2020, 115, 1426-1437.	1.7	27
331	A genome-wide association study of cocaine use disorder accounting for phenotypic heterogeneity and gene–environment interaction. Journal of Psychiatry and Neuroscience, 2020, 45, 34-44.	1.4	27
332	Variation in the Nicotinic Acetylcholine Receptor Gene Cluster CHRNA5–CHRNA3–CHRNB4 and Its Interaction with Recent Tobacco Use Influence Cognitive Flexibility. Neuropsychopharmacology, 2010, 35, 2211-2224.	2.8	26
333	Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Addictive Behaviors, 2011, 36, 156-160.	1.7	26
334	Empirically derived subtypes of opioid use and related behaviors. Addiction, 2011, 106, 1146-1154.	1.7	26
335	Postâ€Treatment Outcomes in a Doubleâ€Blind, Randomized Trial of Sertraline for Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2012, 36, 739-744.	1.4	26
336	Circadian Clock Period Inversely Correlates with Illness Severity in Cells from Patients with Alcohol Use Disorders. Alcoholism: Clinical and Experimental Research, 2013, 37, 1304-1310.	1.4	26
337	<i>FKBP5</i> genotype interacts with early life trauma to predict heavy drinking in college students. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 879-887.	1.1	26
338	Concurrent and Predictive Validity of Antisocial Personality Disorder Subtyping among Substance Abusers. Journal of Nervous and Mental Disease, 1999, 187, 478-486.	0.5	26
339	Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. Journal of Consulting and Clinical Psychology, 1994, 62, 1116-26.	1.6	26
340	No Association of PROP Taster Status and Paternal History of Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 1996, 20, 1496-1500.	1.4	25
341	Multiple <i>OPR</i> genes influence personality traits in substance dependent and healthy subjects in two American populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1028-1039.	1.1	25
342	Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics. Addiction Biology, 2011, 16, 124-132.	1.4	25

#	Article	IF	CITATIONS
343	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders. Neuropsychopharmacology, 2012, 37, 402-411.	2.8	25
344	Missing Data in Alcohol Clinical Trials with Binary Outcomes. Alcoholism: Clinical and Experimental Research, 2016, 40, 1548-1557.	1.4	25
345	Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the <scp>COMBINE</scp> Study. Alcoholism: Clinical and Experimental Research, 2017, 41, 1054-1062.	1.4	25
346	Genetics of drug dependence. Dialogues in Clinical Neuroscience, 2010, 12, 77-84.	1.8	25
347	Characterization of a likelihood based method and effects of markers informativeness in evaluation of admixture and population group assignment. BMC Genetics, 2005, 6, 50.	2.7	24
348	Personality Traits of Agreeableness and Extraversion are Associated with ADH4 Variation. Biological Psychiatry, 2007, 61, 599-608.	0.7	24
349	Adolescent cannabis use increases risk for cocaine-induced paranoia. Drug and Alcohol Dependence, 2010, 107, 196-201.	1.6	24
350	The effects of a <i>MAP2K5</i> microRNA target site SNP on risk for anxiety and depressive disorders. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 175-183.	1.1	24
351	Inter-observer reliability of DSM-5 substance use disorders. Drug and Alcohol Dependence, 2015, 153, 229-235.	1.6	24
352	Genomeâ€wide association metaâ€analysis of age at first cannabis use. Addiction, 2018, 113, 2073-2086.	1.7	24
353	AUDITâ $\in$ C and ICD codes as phenotypes for harmful alcohol use: association with <i>ADH1B</i> polymorphisms in two US populations. Addiction, 2018, 113, 2214-2224.	1.7	24
354	Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcoholism: Clinical and Experimental Research, 1998, 22, 1359-62.	1.4	24
355	Screening for health behaviors in ambulatory clinical settings. Addictive Behaviors, 2002, 27, 737-749.	1.7	23
356	Measurement and Prediction of Medication Compliance in Problem Drinkers. Alcoholism: Clinical and Experimental Research, 2003, 27, 1286-1292.	1.4	23
357	Quantitative real-time PCR for gene dosage determinations in microdeletion genotypes. BioTechniques, 2003, 35, 594-598.	0.8	23
358	CHRM2 variation predisposes to personality traits of agreeableness and conscientiousness. Human Molecular Genetics, 2007, 16, 1557-1568.	1.4	23
359	Mutation screen of theGAD2 gene and association study of alcoholism in three populations. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 183-192.	1.1	23
360	Demographic changes and marker properties affect detection of human population differentiation. BMC Genetics, 2007, 8, 21.	2.7	23

#	Article	IF	CITATIONS
361	Substance dependence low-density whole genome association study in two distinct American populations. Human Genetics, 2008, 123, 495-506.	1.8	23
362	Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers. Journal of Maternal-Fetal and Neonatal Medicine, 2009, 22, 751-758.	0.7	23
363	Comparison of Alcoholism Subtypes as Moderators of the Response to Sertraline Treatment. Alcoholism: Clinical and Experimental Research, 2012, 36, 509-516.	1.4	23
364	Multi-view singular value decomposition for disease subtyping and genetic associations. BMC Genetics, 2014, 15, 73.	2.7	23
365	Pharmacogenetics of alcohol use disorder treatments: an update. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 553-564.	1.5	23
366	Transient Cocaine-Associated Behavioral Symptoms Rated with a New Instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). American Journal on Addictions, 2009, 18, 339-345.	1.3	23
367	Validity of the Distinction Between "Substance-Induced―and "Independent―Depressio and Anxiety Disorders. American Journal on Addictions, 1995, 4, 107-117.	1.3	23
368	Buspirone Treatment of Anxiety in a Patient Dependent on Alprazolam. Journal of Clinical Psychopharmacology, 1989, 9, 153.	0.7	22
369	Confirmation and fine mapping of the chromosome 1 alcohol dependence risk locus. Molecular Psychiatry, 2004, 9, 312-319.	4.1	22
370	GENETIC STUDY: Tryptophan hydroxylase 2 gene and alcohol use among college students. Addiction Biology, 2008, 13, 440-448.	1.4	22
371	Association of Variants in MANEA With Cocaine-Related Behaviors. Archives of General Psychiatry, 2009, 66, 267.	13.8	22
372	Posttreatment Effects of Topiramate Treatment for Heavy Drinking. Alcoholism: Clinical and Experimental Research, 2014, 38, 3017-3023.	1.4	22
373	Deep resequencing of 17 glutamate system genes identifies rare variants in <scp><i>DISC1</i></scp> and <scp><i>GRIN2B</i></scp> affecting risk of opioid dependence. Addiction Biology, 2014, 19, 955-964.	1.4	22
374	Using phenotype risk scores to enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder. Molecular Psychiatry, 2022, 27, 2206-2215.	4.1	22
375	Headaches and Psychoactive Substance Use. Headache, 1991, 31, 584-587.	1.8	21
376	Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholismâ~†. Journal of Substance Abuse Treatment, 1993, 10, 283-287.	1.5	21
377	PROP taster status and parental history of alcohol dependence. Drug and Alcohol Dependence, 1998, 52, 109-113.	1.6	21
378	Rates of Personality Disorders in Substance Abusers: A Comparison Between DSM-III-R and DSM-IV. Journal of Personality Disorders, 1999, 13, 375-384.	0.8	21

#	Article	IF	CITATIONS
379	Using cue reactivity to evaluate medications for treatment of cocaine dependence: a critical review. Addiction, 1999, 94, 1639-1651.	1.7	21
380	An in-frame deletion in the α2C adrenergic receptor is common in African–Americans. Molecular Psychiatry, 2001, 6, 168-172.	4.1	21
381	The Status of Serotonin-Selective Pharmacotherapy in the Treatment of Alcohol Dependence. , 2002, 16, 247-262.		21
382	Effects of rapid tryptophan depletion on mood and urge to drink in patients with co-morbid major depression and alcohol dependence. Psychopharmacology, 2004, 171, 340-348.	1.5	21
383	Insomnia in Alcohol Dependence: Predictors of Symptoms in a Sample of Veterans Referred from Primary Care. American Journal on Addictions, 2013, 22, 266-270.	1.3	21
384	Reductions in Alcohol Craving Following Naltrexone Treatment for Heavy Drinking. Alcohol and Alcoholism, 2016, 51, 562-566.	0.9	21
385	Selfâ€efficacy mediates the effects of topiramate and <scp><i>GRIK1</i></scp> genotype on drinking. Addiction Biology, 2016, 21, 450-459.	1.4	21
386	Genomeâ€wide association study of body mass index in subjects with alcohol dependence. Addiction Biology, 2017, 22, 535-549.	1.4	21
387	Enhancing Discovery of Genetic Variants for Posttraumatic Stress Disorder Through Integration of Quantitative Phenotypes and Trauma Exposure Information. Biological Psychiatry, 2022, 91, 626-636.	0.7	21
388	Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. Alcoholism: Clinical and Experimental Research, 2002, 26, 1330-5.	1.4	21
389	A Serotonin Transporter Gene Polymorphism (5-HTTLPR), Drinking-to-Cope Motivation, and Negative Life Events Among College Students. Journal of Studies on Alcohol and Drugs, 2008, 69, 814-823.	0.6	20
390	Subtypes of major depression in substance dependence. Addiction, 2009, 104, 1700-1709.	1.7	20
391	Examining the effects of alcohol on GABAA receptor mRNA expression and function in neural cultures generated from control and alcohol dependent donor induced pluripotent stem cells. Alcohol, 2018, 66, 45-53.	0.8	20
392	Translational studies support a role for serotonin 2B receptor (HTR2B) gene in aggression-related cannabis response. Molecular Psychiatry, 2018, 23, 2277-2286.	4.1	20
393	Multi-environment gene interactions linked to the interplay between polysubstance dependence and suicidality. Translational Psychiatry, 2021, 11, 34.	2.4	20
394	Genetic underpinnings of risky behaviour relate to altered neuroanatomy. Nature Human Behaviour, 2021, 5, 787-794.	6.2	20
395	The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001–2002 and 2012–2013. American Journal of Psychiatry, 2021, 178, 548-559.	4.0	20
396	Stage of change as a predictor of abstinence among alcoholâ€dependent subjects in pharmacotherapy trials. Substance Abuse, 1998, 19, 81-91.	1.1	19

#	Article	IF	CITATIONS
397	Association of COL25A1 with Comorbid Antisocial Personality Disorder and Substance Dependence. Biological Psychiatry, 2012, 71, 733-740.	0.7	19
398	Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. Drug and Alcohol Dependence, 2019, 201, 16-22.	1.6	19
399	Salivary microRNAs identified by small RNA sequencing and machine learning as potential biomarkers of alcohol dependence. Epigenomics, 2019, 11, 739-749.	1.0	19
400	Post-GWAS analysis of six substance use traits improves the identification and functional interpretation of genetic risk loci. Drug and Alcohol Dependence, 2020, 206, 107703.	1.6	19
401	Validity of the SCID in substance abuse patients. Addiction, 1996, 91, 859-868.	1.7	18
402	Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence. Addiction Biology, 2006, 11, 76-83.	1.4	18
403	Evidence-Based Treatments for Alcohol Dependence. JAMA - Journal of the American Medical Association, 2006, 295, 2075.	3.8	18
404	<i>ADH7</i> variation modulates extraversion and conscientiousness in substanceâ€dependent subjects. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 179-186.	1.1	18
405	Interpopulation linkage disequilibrium patterns of GABRA2 and GABRG1 genes at the GABA cluster locus on human chromosome 4. Genomics, 2008, 91, 61-69.	1.3	18
406	5-HTTLPR genotype and daily negative mood moderate the effects of sertraline on drinking intensity. Addiction Biology, 2013, 18, 1024-1031.	1.4	18
407	Examining FKBP5 mRNA expression in human iPSC-derived neural cells. Psychiatry Research, 2017, 247, 172-181.	1.7	18
408	Effects of a Diagnosis or Family History of Alcoholism on the Taste Intensity and Hedonic Value of Sucrose. American Journal on Addictions, 2009, 18, 494-499.	1.3	17
409	Subgroup Identification in Personalized Treatment of Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2015, 39, 1253-1259.	1.4	17
410	Ancestryâ€specific and sexâ€specific risk alleles identified in a genomeâ€wide geneâ€byâ€alcohol dependence interaction study of risky sexual behaviors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 846-853.	1.1	17
411	Genetic factor common to schizophrenia and HIV infection is associated with risky sexual behavior: antagonistic vs. synergistic pleiotropic SNPs enriched for distinctly different biological functions. Human Genetics, 2017, 136, 75-83.	1.8	17
412	Apolipoprotein E gene polymorphism, posttraumatic stress disorder, and cognitive function in older U.S. veterans: Results from the National Health and Resilience in Veterans Study. Depression and Anxiety, 2019, 36, 834-845.	2.0	17
413	Genome-Wide Meta-Analyses of FTND and TTFC Phenotypes. Nicotine and Tobacco Research, 2020, 22, 900-909.	1.4	17
414	Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. Alcoholism: Clinical and Experimental Research, 2020, 44, 1625-1635.	1.4	17

#	Article	IF	CITATIONS
415	Genome-Wide Association Study of Opioid Cessation. Journal of Clinical Medicine, 2020, 9, 180.	1.0	17
416	Comparison of healthcare utilization among patients treated with alcoholism medications. American Journal of Managed Care, 2010, 16, 879-88.	0.8	17
417	Nutritional Ketosis as a Potential Treatment for Alcohol Use Disorder. Frontiers in Psychiatry, 2021, 12, 781668.	1.3	17
418	Determination of fluvoxamine concentration in plasma by reversed-phase liquid chromatography. Biomedical Chromatography, 1994, 8, 278-282.	0.8	16
419	Variants in the ?2A AR adrenergic receptor gene in psychiatric patients. , 1998, 81, 405-410.		16
420	Medications for Alcohol Dependence—New Vistas. JAMA - Journal of the American Medical Association, 2000, 284, 1016.	3.8	16
421	Ordered subset linkage analysis based on admixture proportion identifies new linkage evidence for alcohol dependence in African-Americans. Human Genetics, 2013, 132, 397-403.	1.8	16
422	FKBP5 variation is associated with the acute and chronic effects of nicotine. Pharmacogenomics Journal, 2015, 15, 340-346.	0.9	16
423	Urgency traits moderate daily relations between affect and drinking to intoxication among young adults. Drug and Alcohol Dependence, 2017, 170, 59-65.	1.6	16
424	Issues in the definition and diagnosis of alcoholism: Implications for a reformulation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 113-128.	2.5	15
425	A double-blind comparison of abecarnil and diazepam in the treatment of uncomplicated alcohol withdrawal. Psychopharmacology, 1997, 131, 123-129.	1.5	15
426	Brief motivational enhancement and coping skills interventions for heavy drinking. Addictive Behaviors, 2007, 32, 1105-1118.	1.7	15
427	Variation in Mu-Opioid Receptor Gene (OPRM1) as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. Journal of Alcoholism and Drug Dependence, 2013, 01, 101.	0.2	15
428	Exploring the genetic architecture of alcohol dependence in African-Americans via analysis of a genomewide set of common variants. Human Genetics, 2014, 133, 617-624.	1.8	15
429	Alcohol and nicotine codependence-associated DNA methylation changes in promoter regions of addiction-related genes. Scientific Reports, 2017, 7, 41816.	1.6	15
430	Validating Harmful Alcohol Use as a Phenotype for Genetic Discovery Using Phosphatidylethanol and a Polymorphism in <i><scp>ADH</scp>1B</i> . Alcoholism: Clinical and Experimental Research, 2017, 41, 998-1003.	1.4	15
431	Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. PLoS ONE, 2020, 15, e0237430.	1.1	15
432	Phenothiazine-Associated Lupus Anticoagulant and Thrombotic Disease. Psychosomatics, 1988, 29, 109-113.	2.5	14

#	Article	IF	CITATIONS
433	Variant detection at the ? opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Human Genetics, 2000, 107, 86-88.	1.8	14
434	Nogo 3′-untranslated region CAA insertion: failure to replicate association with schizophrenia and demonstration of marked population difference in frequency of the insertion. Molecular Brain Research, 2004, 120, 197-200.	2.5	14
435	Association study of DTNBP1 with schizophrenia in a US sample. Psychiatric Genetics, 2009, 19, 292-304.	0.6	14
436	Autosomal linkage scan for loci predisposing to comorbid dependence on multiple substances. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 361-369.	1.1	14
437	The α-endomannosidase gene (MANEA) is associated with panic disorder and social anxiety disorder. Translational Psychiatry, 2014, 4, e353-e353.	2.4	14
438	Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 31±-HSD type 2 (1712-HSD type)	Tj ETQq0 (	) 0 rgBT /Over
439	Nf1 Regulates Alcohol Dependence-Associated Excessive Drinking and Gamma-Aminobutyric Acid Release in the Central Amygdala in Mice and Is Associated with Alcohol Dependence in Humans. Biological Psychiatry, 2015, 77, 870-879.	0.7	14
440	Trauma exposure interacts with the genetic risk of bipolar disorder in alcohol misuse of <scp>US</scp> soldiers. Acta Psychiatrica Scandinavica, 2018, 137, 148-156.	2.2	14
441	Genome-wide association study identifies glutamate ionotropic receptor GRIA4 as a risk gene for comorbid nicotine dependence and major depression. Translational Psychiatry, 2018, 8, 208.	2.4	14
442	Risk Locus Identification Ties Alcohol Withdrawal Symptoms to <i><scp>SORCS</scp>2</i> . Alcoholism: Clinical and Experimental Research, 2018, 42, 2337-2348.	1.4	14
443	Alcohol-responsive genes identified in human iPSC-derived neural cultures. Translational Psychiatry, 2019, 9, 96.	2.4	14
444	Randomized trial of nicotine inhaler for pregnant smokers. American Journal of Obstetrics & Gynecology MFM, 2019, 1, 10-18.	1.3	14
445	Treatment of co-occurring alcohol and other drug use disorders. Alcohol Research, 2008, 31, 155-67.	1.0	14
446	Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. American Journal of Medical Genetics Part A, 2004, 124B, 81-86.	2.4	13
447	CALCYON gene variation, schizophrenia, and cocaine dependence. American Journal of Medical Genetics Part A, 2004, 125B, 25-30.	2.4	13
448	Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behavioral and Brain Functions, 2012, 8, 23.	1.4	13
449	Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence. Alcoholism: Clinical and Experimental Research, 2018, 42, 1249-1259.	1.4	13
450	Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS and Behavior, 2019, 23, 3340-3349.	1.4	13

#	Article	IF	CITATIONS
451	Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder. Neuropsychopharmacology, 2021, 46, 1407-1413.	2.8	13
452	Reward drinking and naltrexone treatment response among young adult heavy drinkers. Addiction, 2021, 116, 2360-2371.	1.7	13
453	Identification of POMC Exonic Variants Associated with Substance Dependence and Body Mass Index. PLoS ONE, 2012, 7, e45300.	1.1	13
454	Alcohol and drug abuse treatment at the University of Connecticut Health Center. Addiction, 1992, 87, 521-526.	1.7	12
455	The effects of naltrexone on alcohol consumption and affect reactivity to daily interpersonal events among heavy drinkers Experimental and Clinical Psychopharmacology, 2006, 14, 199-208.	1.3	12
456	Memantine for Alcohol Dependence: An Open-label Pilot Study. Addictive Disorders and Their Treatment, 2007, 6, 77-83.	0.5	12
457	<i>ADH1A</i> variation predisposes to personality traits and substance dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 376-386.	1.1	12
458	Identification of population substructure among Jews using STR markers and dependence on reference populations included. BMC Genetics, 2010, 11, 48.	2.7	12
459	Agitated depression in substance dependence. Drug and Alcohol Dependence, 2011, 116, 163-169.	1.6	12
460	Variation inâ€, <i>OPRM1</i> â€,and Risk of Suicidal Behavior in Drugâ€Đependent Individuals. American Journal on Addictions, 2012, 21, 5-10.	1.3	12
461	Which alcohol use disorder criteria contribute to the association ofADH1Bwith alcohol dependence?. Addiction Biology, 2016, 21, 924-938.	1.4	12
462	Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder. Frontiers in Psychiatry, 2020, 11, 47.	1.3	12
463	Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. Journal of General Internal Medicine, 2021, 36, 404-412.	1.3	12
464	Sertraline Treatment for Alcohol Dependence: Interactive Effects of Medication and Alcoholic Subtype. , 2000, 24, 1041.		12
465	Giving ethanol to alcoholics in a research setting: its effect on compliance with disulfiram treatment. Addiction, 1990, 85, 119-123.	1.7	11
466	Salty and Sour Taste Characteristics and Risk of Alcoholism. Alcoholism: Clinical and Experimental Research, 2003, 27, 955-961.	1.4	11
467	A revised allele frequency estimate and haplotype analysis of the DBH deficiency mutation IVS1+2T → 0 African- and European-Americans. , 2003, 123A, 190-192.	C in	11
468	Effects of Prenatal Tobacco Exposure on Gene Expression Profiling in Umbilical Cord Tissue. Pediatric Research, 2008, 64, 147-153.	1.1	11

#	Article	IF	CITATIONS
469	ACSL6 Is Associated with the Number of Cigarettes Smoked and Its Expression Is Altered by Chronic Nicotine Exposure. PLoS ONE, 2011, 6, e28790.	1.1	11
470	Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials. Journal of Studies on Alcohol and Drugs, 2014, 75, 335-346.	0.6	11
471	Using DNA methylation to validate an electronic medical record phenotype for smoking. Addiction Biology, 2019, 24, 1056-1065.	1.4	11
472	Differentiating Types of Self-Reported Alcohol Abstinence. AIDS and Behavior, 2020, 24, 655-665.	1.4	11
473	A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder. International Journal of Neuropsychopharmacology, 2021, 24, 89-96.	1.0	11
474	Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial. Neuropsychopharmacology, 2021, 46, 1414-1420.	2.8	11
475	The phenomics and genetics of addictive and affective comorbidity in opioid use disorder. Drug and Alcohol Dependence, 2021, 221, 108602.	1.6	11
476	The impact of removing former drinkers from genomeâ€wide association studies of AUDITâ€C. Addiction, 2021, 116, 3044-3054.	1.7	11
477	Drinking goals and attainment in a naltrexone trial of young adult heavy drinkers Journal of Consulting and Clinical Psychology, 2018, 86, 765-774.	1.6	11
478	ANKRD7 and CYTL1 are novel risk genes for alcohol drinking behavior. Chinese Medical Journal, 2012, 125, 1127-34.	0.9	11
479	Utility of a brief cognitive screening instrument in substance abuse patients: Initial investigation. Journal of Substance Abuse Treatment, 1991, 8, 247-251.	1.5	10
480	Closing the gap between alcoholism research and practice: the case for pharmacotherapy. Psychiatric Services, 1996, 47, 917-920.	1.1	10
481	<i>GABRA2</i> Genotype, Impulsivity, and Body Mass. American Journal on Addictions, 2012, 21, 404-410.	1.3	10
482	Balancing Risk and Benefit in Heavy Drinkers Treated With Topiramate. Journal of Clinical Psychiatry, 2016, 77, e278-e282.	1.1	10
483	A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke. Molecular Psychiatry, 2017, 22, 242-249.	4.1	10
484	Sexâ€specific linkage scans in opioid dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 261-268.	1.1	10
485	Genomeâ€wide scan identifies opioid overdose risk locus close to MCOLN1. Addiction Biology, 2020, 25, e12811.	1.4	10
486	Longitudinal findings from a randomized clinical trial of naltrexone for young adult heavy drinkers Journal of Consulting and Clinical Psychology, 2016, 84, 185-190.	1.6	10

#	Article	IF	CITATIONS
487	Genome-wide meta-analysis of alcohol use disorder in East Asians. Neuropsychopharmacology, 2022, 47, 1791-1797.	2.8	10
488	Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Journal of Clinical Psychiatry, 1996, 57 Suppl 7, 15-21; discussion 22-4.	1.1	10
489	Recessive genetic mode of an ADH4 variant in substance dependence in African-Americans: A model of utility of the HWD test. Behavioral and Brain Functions, 2008, 4, 42.	1.4	9
490	Sources of Unreliability in the Diagnosis of Substance Dependence. Journal of Studies on Alcohol and Drugs, 2009, 70, 475-481.	0.6	9
491	Confirmation and Generalization of an Alcohol-Dependence Locus on Chromosome 10q. Neuropsychopharmacology, 2010, 35, 1325-1332.	2.8	9
492	Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults Experimental and Clinical Psychopharmacology, 2016, 24, 367-375.	1.3	9
493	Effects of LY466195, a selective kainate receptor antagonist, on ethanol preference and drinking in rats. Neuroscience Letters, 2017, 639, 8-12.	1.0	9
494	S100A10 identified in a genome-wide gene × cannabis dependence interaction analysis of risky sexual behaviours. Journal of Psychiatry and Neuroscience, 2017, 42, 252-261.	1.4	9
495	Genomewide Gene-by-Sex Interaction Scans Identify ADGRV1 for Sex Differences in Opioid Dependent African Americans. Scientific Reports, 2019, 9, 18070.	1.6	9
496	An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence. Pharmacogenomics Journal, 2020, 20, 672-680.	0.9	9
497	Genetic liability for substance use associated with medical comorbidities in electronic health records of African―and Europeanâ€ancestry individuals. Addiction Biology, 2022, 27, e13099.	1.4	9
498	ODACH: a one-shot distributed algorithm for Cox model with heterogeneous multi-center data. Scientific Reports, 2022, 12, 6627.	1.6	9
499	Patient Predictors of Irregular Discharge From Inpatient Substance Abuse Treatment. American Journal on Addictions, 1994, 3, 122-128.	1.3	8
500	Self-Efficacy as a Predictor of Relapse During Treatment for Alcohol Dependence. Addictive Disorders and Their Treatment, 2003, 2, 135-145.	0.5	8
501	Population admixture modulates risk for alcohol dependence. Human Genetics, 2009, 125, 605-613.	1.8	8
502	Analysis of extreme drinking in patients with alcohol dependence using Pareto regression. Statistics in Medicine, 2010, 29, 1250-1258.	0.8	8
503	Variation in <i>NGFB</i> is associated with primary affective disorders in women. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 401-412.	1.1	8
504	Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response. Drug and Alcohol Dependence, 2022, 232, 109257.	1.6	8

#	Article	IF	CITATIONS
505	Atypical Koro. British Journal of Psychiatry, 1988, 152, 579-580.	1.7	7
506	Persistent Urinary Benzoylecgonine Following Cocaine Use. American Journal on Addictions, 1992, 1, 265-271.	1.3	7
507	Incentive program decreases no-shows in nontreatment substance abuse research Experimental and Clinical Psychopharmacology, 2005, 13, 376-380.	1.3	7
508	Effects of Naltrexone Treatment for Alcoholâ€Related Disorders on Healthcare Costs in an Insured Population. Alcoholism: Clinical and Experimental Research, 2010, 34, 1090-1097.	1.4	7
509	Should the Reorganization of Addiction-Related Research Across All the National Institutes of Health Be Structural?-The Devil Is Truly in the Details. Alcoholism: Clinical and Experimental Research, 2011, 35, 572-580.	1.4	7
510	Multi-view biclustering for genotype-phenotype association studies of complex diseases. , 2013, , .		7
511	GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate Experimental and Clinical Psychopharmacology, 2014, 22, 494-501.	1.3	7
512	Eye color: A potential indicator of alcohol dependence risk in European Americans. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 347-353.	1.1	7
513	Epigenomic Profiles of African-American Transthyretin Val1221le Carriers Reveals Putatively Dysregulated Amyloid Mechanisms. Circulation Genomic and Precision Medicine, 2021, 14, e003011.	1.6	7
514	Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder. Psychological Medicine, 2023, 53, 1196-1204.	2.7	7
515	World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials. Alcoholism: Clinical and Experimental Research, 2021, 45, 1664-1671.	1.4	7
516	Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. Drug and Alcohol Dependence, 2021, 225, 108762.	1.6	7
517	An Effective Method to Identify Heritable Components from Multivariate Phenotypes. PLoS ONE, 2015, 10, e0144418.	1.1	7
518	Critical evaluation of transcription factor Atf2 as a candidate modulator of alcohol preference in mouse and human populations. Genetics and Molecular Research, 2013, 12, 5992-6005.	0.3	7
519	Alcohol use and alcohol use disorder differ in their genetic relationships with PTSD: A genomic structural equation modelling approach. Drug and Alcohol Dependence, 2022, 234, 109430.	1.6	7
520	Translating the Semi-Structured Assessment for Drug Dependence and Alcoholism in the Western Pacific: Rationale, Study Design and Reliability of Alcohol Dependence. Alcohol and Alcoholism, 2014, 49, 525-530.	0.9	6
521	Characteristics and Course of Dependence in Cocaine-Dependent Individuals Who Never Used Alcohol or Marijuana or Used Cocaine First. Journal of Studies on Alcohol and Drugs, 2014, 75, 423-427.	0.6	6
522	Topiramate's reduction of body mass index in heavy drinkers: Lack of moderation by a GRIK1 polymorphism Experimental and Clinical Psychopharmacology, 2014, 22, 419-423.	1.3	6

#	Article	IF	CITATIONS
523	Effects of Recent Alcohol Consumption Level on Neurocognitive Performance in HIV+ Individuals. Addictive Disorders and Their Treatment, 2017, 16, 95-107.	0.5	6
524	Opioid Use and Rate of Nicotine Metabolism Among Pregnant Smokers. Nicotine and Tobacco Research, 2020, 22, 1046-1050.	1.4	6
525	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. Exploration of Medicine, 2021, 2, 60-73.	1.5	6
526	Accuracy of Consumerâ€marketed smartphoneâ€paired alcohol breath testing devices: A laboratory validation study. Alcoholism: Clinical and Experimental Research, 2021, 45, 1091-1099.	1.4	6
527	Antagonism of CluK1-containing kainate receptors reduces ethanol consumption by modulating ethanol reward and withdrawal. Neuropharmacology, 2021, 199, 108783.	2.0	6
528	Ancestry may confound genetic machine learning: Candidate-gene prediction of opioid use disorder as an example. Drug and Alcohol Dependence, 2021, 229, 109115.	1.6	6
529	Sodium chloride treatment of antidepressant-induced orthostatic hypotension. Journal of Clinical Psychiatry, 1988, 49, 366-8.	1.1	6
530	Major Depression and PTSD in Pregnant Smokers Enrolled in Nicotine Gum Treatment Trial. American Journal on Addictions, 2013, 22, 54-59.	1.3	5
531	Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials, 2018, 19, 443.	0.7	5
532	Long-term use of hydrocodone vs. oxycodone in primary care. Drug and Alcohol Dependence, 2019, 205, 107524.	1.6	5
533	Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial. Contemporary Clinical Trials, 2021, 101, 106247.	0.8	5
534	Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis. Alcoholism: Clinical and Experimental Research, 2001, 25, 1335-1341.	1.4	5
535	Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research. BMC Genetics, 2007, 8, 71.	2.7	4
536	Evaluating the role of a galanin enhancer genotype on a range of metabolic, depressive and addictive phenotypes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 654-664.	1.1	4
537	<i>&gt;5â€<scp>HTTLPR</scp></i> Moderates Naltrexone and Psychosocial Treatment Responses in Heavy Drinking Men Who Have Sex with Men. Alcoholism: Clinical and Experimental Research, 2014, 38, 2362-2368.	1.4	4
538	What happens when people discontinue taking medications? Lessons from COMBINE. Addiction, 2014, 109, 2044-2052.	1.7	4
539	Smoking and Cellular Telephone Use Among Pregnant Women Seeking Prenatal Care. Addictive Disorders and Their Treatment, 2015, 14, 203-210.	0.5	4
540	Genomeâ€wide association study of cognitive flexibility assessed by the Wisconsin Card Sorting Test. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 511-519.	1.1	4

#	Article	IF	CITATIONS
541	Longitudinal Drinking Patterns and Their Clinical Correlates in Million Veteran Program Participants. Alcoholism: Clinical and Experimental Research, 2019, 43, 465-472.	1.4	4
542	Placebo-controlled trial of bupropion for smoking cessation in pregnant women. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100315.	1.3	4
543	Genome-wide association study of stimulant dependence. Translational Psychiatry, 2021, 11, 363.	2.4	4
544	Reliability and validity of DSM-IV and DSM-5 methamphetamine use disorder diagnoses using the Chinese Version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Drug and Alcohol Dependence, 2021, 229, 109047.	1.6	4
545	Effect of Maternal Smoking on Fetal Catecholamine Concentrations at Birth. , 0, .		4
546	Circadian Pattern of Deaths Due to Suicide in Intoxicated Alcohol-Dependent Individuals. Journal of Clinical Psychiatry, 2018, 79, .	1.1	4
547	Identifying and Reducing Bias in Genome-Wide Association Studies of Alcohol-Related Traits. American Journal of Psychiatry, 2022, 179, 14-16.	4.0	4
548	Postâ€treatment effects of topiramate on alcoholâ€related outcomes: A combined analysis of two placeboâ€controlled trials. Addiction Biology, 2022, 27, e13130.	1.4	4
549	Within―and betweenâ€person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. Alcoholism: Clinical and Experimental Research, 2022, 46, 477-491.	1.4	4
550	Alcohol withdrawal in pastâ€year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey. Alcoholism: Clinical and Experimental Research, 2022, 46, 422-433.	1.4	4
551	Mental Disorders; Alcohol- and Drug-Related Problems: International Perspectives on Their Diagnosis and Classification. Journal of Studies on Alcohol and Drugs, 1988, 49, 384-385.	2.4	3
552	Is the medication bottle half full or half empty?. Addiction, 1997, 92, 951-953.	1.7	3
553	Title is missing!. Substance Abuse, 1998, 19, 81-91.	1.1	3
554	Response to Dr. Kopke's comments on haplotypes at the OPRM1 locus. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 135B, 102-102.	1.1	3
555	The efficacy and safety of a fixed versus titrated dosage regimen of nicotine gum for smoking cessation or reduction in pregnancy. American Journal of Obstetrics and Gynecology, 2006, 195, S89.	0.7	3
556	Quadratic optimization to identify highly heritable quantitative traits from complex phenotypic features. , 2013, , .		3
557	Commentary on Garbutt <i>et al</i> . (2014): Can we predict who benefits from naltrexone in the treatment of alcohol dependence?. Addiction, 2014, 109, 1285-1286.	1.7	3
558	Multiview Comodeling to Improve Subtyping and Genetic Association of Complex Diseases. IEEE Journal of Biomedical and Health Informatics, 2014, 18, 548-554.	3.9	3

#	Article	IF	CITATIONS
559	Ttn as a likely causal gene for QTL of alcohol preference on mouse chromosome 2. BMC Bioinformatics, 2014, 15, P12.	1.2	3
560	Refining multivariate disease phenotypes for high chip heritability. BMC Medical Genomics, 2015, 8, S3.	0.7	3
561	A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans. Translational Psychiatry, 2019, 9, 309.	2.4	3
562	Molecular Correlates of Topiramate and <i>GRIK1</i> rs2832407 Genotype in Pluripotent Stem Cell–Derived Neural Cultures. Alcoholism: Clinical and Experimental Research, 2020, 44, 1561-1570.	1.4	3
563	Diagnostic Reliability and Validity of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) Chinese Version. Complex Psychiatry, 2020, 6, 62-67.	1.3	3
564	Salty and sour taste characteristics and risk of alcoholism. Alcoholism: Clinical and Experimental Research, 2003, 27, 955-61.	1.4	3
565	Psychosocial Issues Concerning a Pregnant Adolescent with Hodgkin's Disease. Journal of Psychosocial Oncology, 1987, 5, 83-89.	0.6	2
566	Extended-Release Intramuscular Naltrexone. Drugs, 2006, 66, 1752-1754.	4.9	2
567	Medications to treat heavy drinking: are we there yet?. Addiction, 2006, 101, 153-154.	1.7	2
568	How Should Addiction-Related Research at the National Institutes of Health be Reorganized?. Frontiers in Psychiatry, 2011, 2, 2.	1.3	2
569	A multi-objective program for quantitative subtyping of clinically relevant phenotypes. , 2012, , .		2
570	Induced pluripotent stem cell reprogrammingâ€associated methylation at the GABRA2 promoter and chr4p12 GABA A subunit gene expression in the context of alcohol use disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 464-474.	1.1	2
571	Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. Nicotine and Tobacco Research, 2020, 22, 1923-1927.	1.4	2
572	Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. Journal of Affective Disorders, 2021, 282, 1272-1277.	2.0	2
573	Analysis of genetic and clinical factors associated with buprenorphine response. Drug and Alcohol Dependence, 2021, 227, 109013.	1.6	2
574	Association Study of Alcoholism Subtypes with a Functional Promoter Polymorphism in the Serotonin Transporter Protein Gene. , 2002, 26, 1330.		2
575	What is addiction?. Alcohol Research, 2008, 31, 93-5.	1.0	2
576	ls it time to rethink lowâ€risk drinking guidelines?. Alcoholism: Clinical and Experimental Research, 2022, 46, 700-701.	1.4	2

#	Article	IF	CITATIONS
577	The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects. Behavioural Pharmacology, 2022, Publish Ahead of Print, .	0.8	2
578	Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. Neuropsychopharmacology, 2022, 47, 1784-1790.	2.8	2
579	Substance Use Disorders in Patients With Chronic Fatigue. Psychiatric Services, 1991, 42, 924-928.	1.1	1
580	Intragastric Infusion of Ethanol by Alcoholics After Surgery for Head and Neck Cancer. American Journal on Addictions, 1992, 1, 83-85.	1.3	1
581	Letter to the editor. Addictive Behaviors, 1993, 18, 599-600.	1.7	1
582	No allelic association of an exon 13 polymorphism of the Gsα gene to alcohol and/or drug dependence. Addiction Biology, 1997, 2, 309-316.	1.4	1
583	Treatment of alcohol dependence. Liver Transplantation, 1997, 3, 311-321.	1.9	1
584	How to measure relapse in humans. , 2005, , 23-39.		1
585	A genomewide ordered-subset linkage analysis for alcohol dependence in African-Americans. Genome Biology, 2010, 11, O6.	13.9	1
586	Endorsement of the <scp>CONSORT</scp> Principles in Reporting Alcohol Clinical Trials in <i><scp>ACER</scp></i> . Alcoholism: Clinical and Experimental Research, 2015, 39, 1556-1556.	1.4	1
587	Further analyses support the association between light eye color and alcohol dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 757-760.	1.1	1
588	New Initiatives for <i>Alcoholism: Clinical and Experimental Research</i> . Alcoholism: Clinical and Experimental Research, 2016, 40, 652-652.	1.4	1
589	908. Genome-Wide Association Study Identifies HTR2B as a Risk Variant of Cannabis-Related Aggression in African Americans. Biological Psychiatry, 2017, 81, S367.	0.7	1
590	Collaborative phenotype inference from comorbid substance use disorders and genotypes. , 2017, 2017, 392-397.		1
591	Predictors of Treatment Referral After AUDIT-C Screening for Heavy Drinking. Addictive Disorders and Their Treatment, 2018, 17, 124-133.	0.5	1
592	F123. Genome-Wide Epigenetic Signatures of Major Depressive Disorder in Women. Biological Psychiatry, 2018, 83, S285.	0.7	1
593	GWAS and network analysis of coâ€occurring nicotine and alcohol dependence identifies significantly associated alleles and network. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 3-11.	1.1	1
594	Mecamylamine Modifies the Pharmacokinetics and Reinforcing Effects of Alcohol. , 2002, 26, 326.		1

594 Mecamylamine Modifies the Pharmacokinetics and Reinforcing Effects of Alcohol. , 2002, 26, 326.

#	Article	IF	CITATIONS
595	Identifying factors associated with opioid cessation in a biracial sample using machine learning. , 2020, 1, 27-41.		1
596	Identifying Clinical Risk Factors for Opioid Use Disorder using a Distributed Algorithm to Combine Real-World Data from a Large Clinical Data Research Network. AMIA Annual Symposium proceedings, 2020, 2020, 1220-1229.	0.2	1
597	Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. Addiction, 2022, 117, 2826-2836.	1.7	1
598	The Effect of Cigarette Smoking on Fetal Heart Rate Characteristics. Obstetrics and Gynecology, 2002, 100, 829.	1.2	0
599	Genetic variation and drug dependence risk factors. , 2002, , 372-388.		Ο
600	Topiramate as Treatment for Alcohol Dependence—Reply. JAMA - Journal of the American Medical Association, 2008, 299, .	3.8	0
601	A Functional Serotonin Transporter Gene Polymorphism and Depressive Effects Associated With Interferon-α Treatment. Psychosomatics, 2010, 51, 137-148.	2.5	Ο
602	Identifying heritable composite traits from multivariate phenotypes and genome-wide SNPs. , 2014, , .		0
603	ACER:Quo Vadis?. Alcoholism: Clinical and Experimental Research, 2014, 38, 2159-2159.	1.4	0
604	Genetic Factor Common To Schizophrenia And Hiv Infection Is Associated With Risky Sexual Behavior. European Neuropsychopharmacology, 2017, 27, S460-S461.	0.3	0
605	Inferring phenotypes from substance use via collaborative matrix completion. BMC Systems Biology, 2018, 12, 104.	3.0	0
606	F131. Genome-Wide Association Study Identifies Glutamate Ionotropic Receptor GRIA4 as a Risk Gene for Comorbid Nicotine Dependence and Major Depression. Biological Psychiatry, 2018, 83, S288-S289.	0.7	0
607	New and Revised Policies for Alcoholism: Clinical and Experimental Research (ACER ). Alcoholism: Clinical and Experimental Research, 2018, 42, 1570-1571.	1.4	Ο
608	EXPLORING THE ROLE OF GENETIC REGULATION OF GENE EXPRESSION IN SUBSTANCE USE AND DEPENDENCE. European Neuropsychopharmacology, 2019, 29, S803-S804.	0.3	0
609	GENOME-WIDE ASSOCIATION STUDY OF COMORBID ALCOHOL DEPENDENCE AND MAJOR DEPRESSION. European Neuropsychopharmacology, 2019, 29, S971.	0.3	0
610	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. Exploration of Medicine, 0, , .	1.5	0
611	Policy changes for <i>Alcoholism: Clinical and Experimental Research (ACER)</i> . Alcoholism: Clinical and Experimental Research, 2021, 45, 898-898.	1.4	0
612	Association of Alcohol or Other Drug Dependence with Alleles of the ?? Opioid Receptor Gene (OPRM1). Alcoholism: Clinical and Experimental Research, 1998, 22, 1359.	1.4	0

#	Article	IF	CITATIONS
613	Novel digital approaches to the assessment of problematic opioid use. BioData Mining, 2022, 15, .	2.2	0